908 Devices (MASS) Q2 FY26 earnings call: guidance and Q&A

To what extent do bundling opportunities exist across the broader product portfolio (FTR, mass spec, NearLab) for government and law enforcement agencies, and are multi-system orders common?

Bundling opportunities are significant, especially with FTR and mass spec products. The combined portfolio (MX, NearLab, Viper) creates a complete workflow for law enforcement, from screening to confirmation. Multi-unit, multi-system orders are common, and similar bundling applies to HAZMAT/fire services with Explorer and Threat ID.

“I think that's one of the big advantages we've been having as we scale here with FTR portfolio now coupled with mass spec. And now we have Nearlab thrown in here. We're absolutely seeing and have many examples of bundled orders where they may order a couple of FTR products. or a couple of MX products.”

asked by Daniel Arias · answered by Kevin Knopp

How would a more direct path for the AVCAD program (e.g., using commercial off-the-shelf products) impact the revenue ramp and potential in 2027 and 2028, given the current delays?

The AVCAD program is taking longer than expected, but confidence in winning remains high. A shift to commercial off-the-shelf (COTS) products like MX-908 would likely improve economics for 908 Devices due to more direct product content. The program is now considered upside to 2026 guidance, and while the ramp to a $10M+ opportunity is TBD, the long-term potential is strong.

“From an economic side, yes, I think it's clear that the more product content we provide, whichever path they choose is better on the economics for us. From a ramp, as Joe mentioned, we have taken it out of the guide for today and taking it to upside.”

asked by Daniel Arias · answered by Kevin Knopp

What cross-selling opportunities are emerging with NearLab, and how is demand evolving across end markets with the expanded product catalog?

NearLab integration is progressing well, with rapid introduction to existing MX customers in the US. It offers complementary analyte capabilities (e.g., THC quantification) and a different price point to expand market reach. The changing regulations banning colorimetric test kits provide a durable tailwind. The portfolio effect is developing, with bi-directional benefits for both domestic and international markets.

“We're very happy with how the NearLab integration is going. We've really been working hard to get out there fast. Part of the thesis was bringing this product into the US markets where they've had very, very little to none penetration. And to your point, right, we can bring that right to the customers of our core flagship MX-908, right to those law enforcement customers.”

asked by Brendan Smith · answered by Kevin Knopp

What is the ideal or feasible proportion of total revenues from recurring sources over the next couple of years, especially with new launches like NearLab?

Recurring revenue was about 30% this quarter. While it can fluctuate quarterly based on large device orders, the aspiration is to creep up into the 30s, approaching 40%. NearLab's subscription model, with 50% recurring revenue opportunity per device and high annual recurring revenue (ARR) retention, is a key driver for this growth.

“But over time, I think that's where it gets exciting, especially with NearLab and the subscription model. More and more of a... It carries 50% of recurring revenue opportunity with those subscriptions, you have the snowball effect of the install base. So I think starting to creep up into the 30s, kind of approaching that 40% is what we aspire to.”

asked by Brendan Smith · answered by Joseph Griffith

Given the Q2 revenue of $16 million and the AVCAD program moving out of guidance, how will revenue progress in H2, and how much of the $6 million protector order will be recognized in 2026?

H2 revenue is expected to be higher, with a slightly heavier weighting in Q3 compared to Q4. The $6 million protector order is anticipated to be split over Q3 and Q4. Key growth drivers for H2 include Viper shipments (potentially 100-150 units), continued Xplor growth, the protector order, and approximately $1.25 million from NearLab in H2.

“Specifically on the $6 million protector order, we do anticipate that to be split over Q3 and Q4. So we'll see some revenues here in Q3 as we build the number of devices and some go out in the fourth quarter.”

asked by Matthew Larew · answered by Joseph Griffith

What is the current cloud attach rate for devices, the target, and the incremental revenue potential from integrating devices into a cloud platform?

The company aims for greater connectivity and an ecosystem for its products, leveraging the NearLab model. NearLab devices have a 50% recurring revenue component (e.g., $5,000/year subscription for a $10,000 device), with high annual recurring revenue (ARR) retention (>90%). While the overall recurring revenue is currently around 30%, the NearLab model is an aspiration for the entire portfolio over time, offering visibility through multi-year subscriptions.

“Neuralab is a purchase where 50% is recurring. So, nominally list price around $10,000 for the device and nominally around $5,000 per year for the subscription and being able to support that customer with upgrades, new threat assessments, new drugs, new analytes that can be added over time.”

asked by Puneet Souda · answered by Kevin Knopp

What trends are observed in Viper placements (single vs. multi-device, new vs. existing customers), and how is the pipeline shaping up for H2?

Viper has been a very successful launch, with shipments passing 100 units. The company sees single, double, tens, and even 15-unit orders. It's leveraging the modernization cycle globally, driven by increased funding for responders and NATO entities. The pipeline is strong, and Viper is a key growth driver for H2, with expectations to exceed 100 and potentially approach 150 shipments for the full year.

“I mean, I think Viper is a really successful launch for us. It's the first launch under the red wave with 908 as one here, calling it our Viper product together launch to the market. Super successful thus far, very pleased with those, call it passing 100 units successfully I think we're seeing this take advantage of the modernization cycle that's setting up across the globe, whether it's funded from the state and local and the increase of funding that's available to responders or across NATO entities. And we've certainly seen singles, doubles, tens, even 15-unit type orders coming in one go.”

asked by Max Masucci · answered by Kevin Knopp